Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

The new pens will eventually be phased in to replace NovoPen 5 and NovoPen Echo in countries where those devices are already available. Last year Glooko and Novo Nordisk launched the ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

The European Medicines Agency warned about pre-filled pens falsely labeled as Novo Nordisk A/S's (NYSE: NVO) popular diabetes drug Ozempic at wholesalers in the European Union and the U.K. The ...

Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as ...

Novo Business Checking Review (2024): Is Novo a Trusted Bank? Your email has been sent You might be wondering if Novo is the right fit for your business? In the following sections we’ll be ...

James Manning / PA Images / Getty Images After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...

Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.

LONDON, Nov 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk Knudsen said on an ...

Novo Nordisk’s weight loss drug Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, results the company sees as ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start catching up. Less than a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...